Fulvedex 250mg/5ml Inj. 1`s

A healthcare professional administers it as an intramuscular injection into each buttock on a monthly schedule.

Fulvedex 250mg/5ml Injection Ingredients and Usage

Fulvedex 250mg/5ml Injection contains fulvestrant, a selective estrogen receptor degrader belonging to the pure anti-estrogen drug class. Doctors prescribe it for hormone receptor positive, HER2 negative advanced or metastatic breast cancer in postmenopausal women, either as first line therapy or after disease progression on prior endocrine treatment.

Fulvedex 250mg/5ml Injection is given as two 250mg injections, one into each buttock, on days 1, 15, and 29, then monthly thereafter. It may be used alone or combined with CDK4/6 inhibitors such as palbociclib, ribociclib, or abemaciclib.

How Does Fulvedex 250mg/5ml Injection Work?

Fulvestrant competitively binds to estrogen receptors on breast cancer cells and blocks estrogen from attaching. Unlike tamoxifen, it does not act as a partial estrogen agonist, making it a pure anti-estrogen.

Once bound, fulvestrant causes the estrogen receptor to break down, reducing the total number of receptors available on the cell surface. By degrading these receptors, Fulvedex 250mg/5ml Injection shuts down estrogen driven signaling that fuels the growth of hormone receptor positive breast cancer cells.

Fulvedex 250mg/5ml Injection Side Effects

Fulvedex 250mg/5ml Injection commonly causes injection site and general side effects.

• Injection site pain

• Hot flashes

• Nausea

• Fatigue and weakness

• Headache

• Joint and back pain

• Elevated liver enzymes

Warnings

• Fulvedex 250mg/5ml Injection can cause embryo-fetal harm and is contraindicated in pregnancy; women of reproductive potential must use effective contraception during treatment.

• Use with caution in patients on anticoagulants or with bleeding disorders, since the intramuscular injection carries a bleeding risk.

• Reduced dosing is required in patients with moderate hepatic impairment, since elevated plasma concentrations can occur; avoid use in severe hepatic impairment.

• Avoid breastfeeding during treatment, since it is not known whether fulvestrant passes into breast milk.

• Report any unusual bleeding, bruising, or injection site reactions to the treating doctor promptly.

• The intramuscular injection should be given slowly, over 1 to 2 minutes per site, by a trained healthcare professional only.

Fulvedex 250mg/5ml Injection Storage Conditions

Store Fulvedex 250mg/5ml Injection refrigerated between 2°C and 8°C, and do not freeze. Keep the syringe in its original carton to protect it from light until immediately before use. Store this medicine out of reach of children and ensure only trained healthcare staff handle administration.